Watch STOK. Know when insiders buy.
One email the day a filing lands. Free.
STOK
Stoke Therapeutics, Inc.
25.68
−0.93 −3.49%
USD · close Oct 21
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
66
PASS · insiders 41, shorts 90
Insiders, 90 days
−$187K
net selling · 0 buys, 3 sells
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $1.7BP/E —DIV YIELD —FCF YIELD -10.90%REV TTM $27.6M −86.2%NET INCOME −$207.9M −496.1%NET CASH —52W 22.37 – 38.35NEXT EARNINGS Nov 3 EST.SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $9.3M | −32.5% | — | −$65.4M | −$61.6M | — | -0.93 | −$56.6M | $2M | −$58.6M | Aug 3 |
| Q1 2026 · Mar 31 | $6.2M | −96.1% | — | −$53.4M | −$50M | −144.3% | -0.79 | −$60.6M | $353K | −$60.9M | Aug 3 |
| Q4 2025 · Dec 31derived | $1.4M | −93.8% | — | −$61.4M | −$57.9M | — | -0.97 | −$30.5M | $232K | −$30.7M | Mar 16 |
| Q3 2025 · Sep 30 | $10.6M | +117.2% | — | −$43.1M | −$38.3M | — | -0.65 | −$30.4M | $132K | −$30.5M | Nov 4 |
| Q2 2025 · Jun 30 | $13.8M | +186.0% | — | −$27.3M | −$23.5M | — | -0.40 | −$25.4M | $154K | −$25.6M | Aug 3 |
| Q1 2025 · Mar 31 | $158.6M | +3661.1% | — | $111.2M | $112.9M | — | 1.90 | $131.8M | $152K | $131.7M | Aug 3 |
| Q4 2024 · Dec 31derived | $22.6M | +707.1% | — | −$13.7M | −$10.5M | — | -0.17 | −$23.2M | $42K | −$23.2M | Mar 16 |
| Q3 2024 · Sep 30 | $4.9M | +47.9% | — | −$30M | −$26.4M | — | -0.47 | −$21.6M | $103K | −$21.7M | Nov 4 |
| Q2 2024 · Jun 30 | $4.8M | — | — | −$29.3M | −$25.7M | — | -0.46 | −$17.5M | $46K | −$17.5M | Nov 4 |
| Q1 2024 · Mar 31 | $4.2M | — | — | −$28.4M | −$26.4M | — | -0.57 | −$24.6M | $12K | −$24.6M | Nov 4 |
| Q4 2023 · Dec 31derived | $2.8M | — | — | −$29.6M | −$27M | — | -0.60 | −$20.6M | $229K | −$20.9M | Mar 18 |
| Q3 2023 · Sep 30 | $3.3M | — | — | −$27.2M | −$24.5M | — | -0.55 | −$17.3M | $383K | −$17.6M | Nov 5 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $184.4M | — | −$20.6M | −$6.9M | -3.7% | -0.12 | $45.6M | $670K | $44.9M | — | — |
| FY2024 · to Dec 31 | $36.6M | — | −$101.4M | −$89M | -243.4% | -1.65 | −$86.9M | $203K | −$87.1M | — | — |
| FY2023 · to Dec 31 | $8.8M | — | −$114.8M | −$104.7M | -1192.5% | -2.38 | −$81.1M | $1.6M | −$82.7M | — | — |
| FY2022 · to Dec 31 | $12.4M | — | −$104.4M | −$101.1M | -814.7% | -2.60 | −$31.9M | $4M | −$35.8M | — | — |
| FY2021 · to Dec 31 | — | — | −$86.1M | −$85.8M | — | -2.34 | −$66.9M | $1.2M | −$68.1M | — | — |
| FY2020 · to Dec 31 | — | — | −$53M | −$52.2M | — | -1.56 | −$42.2M | $1.1M | −$43.3M | — | — |
Every number comes from Stoke Therapeutics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.